Survival outcomes with venetoclax. Median PFS was 3.7 months (A) and median OS was 12.5 months (B). (C-D) PFS and OS in patients treated with venetoclax monotherapy vs in those treated with combination therapy. (E-F) PFS and OS based on the best response to prior treatment with BTKis.